Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Safety and Efficacy of Tegileridine in Painless Gastrointestinal Endoscopy

13 november 2026 bijgewerkt door: Fangpeng Gao, Hainan Medical College

This single-center, randomized, double-blind, active-controlled clinical trial aims to evaluate the safety and efficacy of tegileridine, a biased μ-opioid receptor agonist, in patients undergoing gastrointestinal endoscopy under sedation, compared with sufentanil. A total of 338 patients scheduled for gastrointestinal endoscopy under sedation were enrolled and randomly assigned in a 1:1 ratio to receive either tegileridine or sufentanil. The primary outcome is the incidence of respiratory depression. Secondary outcomes include the incidences of hypotension and postoperative nausea and vomiting, sedation success rate, supplemental propofol dose, procedure duration, recovery time, and patient satisfaction. This study will provide clinical evidence to support individualized and precision-based anesthesia strategies for gastrointestinal endoscopy.

Studie Overzicht

Toestand

Werving

Conditie

Interventie / Behandeling

Gedetailleerde beschrijving

Background: Gastrointestinal endoscopy under sedation is a cornerstone of the diagnosis and treatment of digestive diseases, reducing patient discomfort and improving adherence. Conventional anesthesia with sufentanil and propofol is associated with significant adverse effects, including respiratory depression, gastrointestinal adverse reactions, postoperative nausea and vomiting (PONV), and hemodynamic fluctuations. Tegileridine mediates analgesia through preferential activation of G protein signaling at the μ-opioid receptor while reducing β-arrestin pathway activation, thereby lowering the risks of gastrointestinal adverse reactions and respiratory depression. To date, no clinical studies have investigated tegileridine for gastrointestinal endoscopy under sedation, and pharmacokinetic data and dose-adjustment guidelines for older adults remain unavailable.

Objectives: To systematically compare the safety and efficacy of tegileridine and sufentanil for gastrointestinal endoscopy under sedation, establish the suitability of tegileridine in this setting, and determine an appropriate dose for older patients, thereby supporting the development of individualized and precision-based anesthesia strategies.

Study Design: This is a single-center, randomized, double-blind, active-controlled trial. A total of 338 patients scheduled for gastrointestinal endoscopy under sedation will be enrolled and randomly assigned in a 1:1 ratio to the tegileridine group or the sufentanil group. Participants, staff involved in administering sedation, and outcome assessors will be blinded to treatment allocation. Only the nurses responsible for preparing the study medications will be unblinded.

Study Population: Eligible patients will be aged 18-75 years, have a body mass index (BMI) of 18.0-28.0 kg/m², a Mallampati airway classification of I or II, and an American Society of Anesthesiologists (ASA) physical status classification of I or II, have no contraindications to routine gastroscopy, and provide written informed consent. Exclusion criteria include severe cardiopulmonary disease, hepatic or renal failure, a history of opioid allergy, chronic opioid dependence, hypokalemia, a history of QT interval prolongation, pregnancy, and breastfeeding. Patients whose gastroscopy lasts longer than 30 minutes or who experience adverse events that cannot be resolved with treatment will be withdrawn from the study.

Interventions: Patients in the tegileridine group will receive intravenous tegileridine at 0.01 mg/kg, followed 3 minutes later by intravenous propofol at 1.5 mg/kg. Patients in the sufentanil group will receive intravenous sufentanil at 0.1 μg/kg, followed 3 minutes later by intravenous propofol at 1.5 mg/kg. The procedure will begin once the eyelash reflex is absent and the Modified Observer's Assessment of Alertness/Sedation (MOAA/S) score is ≤3. If signs of inadequate anesthesia occur during the examination, such as body movement, coughing, or a heart rate >100 beats/min, supplemental propofol at 0.5-1.0 mg/kg will be administered at intervals of at least 2 minutes.

Outcome Measures: The primary outcome is the incidence of respiratory depression, defined as a respiratory rate <8 breaths/min or peripheral oxygen saturation (SpO₂) <90%. Secondary outcomes include safety measures (hypotension, PONV, the need for airway interventions, and changes in vital signs at multiple time points), efficacy measures (sedation success rate, the number of supplemental propofol doses and total propofol dose, procedure duration, and recovery time), and patient satisfaction, assessed on a scale of 1-10.

Expected Results: Compared with the sufentanil group, the tegileridine group is expected to have a lower incidence of respiratory depression, a lower risk of PONV, and more stable vital signs while achieving adequate analgesia for gastrointestinal endoscopy under sedation. Tegileridine may therefore offer a safer anesthesia option for older patients and patients with obesity.

Studietype

Ingrijpend

Inschrijving (Geschat)

338

Fase

  • Fase 4

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

  • Naam: Fang Peng Gao, MS
  • Telefoonnummer: 17760577442
  • E-mail: gao1664@163.com

Studie Locaties

    • Hainan
      • Haikou, Hainan, China, 570311
        • Werving
        • The Second Affiliated Hospital of Hainan Medical University
        • Contact:

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar tot 75 jaar (Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Inclusion Criteria:

  1. Patients aged 18-75 years scheduled for gastrointestinal endoscopy under sedation.
  2. Body mass index (BMI) of 18.0-28.0 kg/m².
  3. Mallampati airway classification of I or II.
  4. American Society of Anesthesiologists (ASA) physical status classification of I or II.
  5. No contraindications to routine gastroscopy.
  6. Written informed consent signed by the patient and their family member.

Exclusion Criteria:

  1. Severe cardiopulmonary disease.
  2. Hepatic or renal failure.
  3. History of opioid allergy.
  4. Chronic opioid dependence.
  5. Hypokalemia or a history of QT interval prolongation.
  6. Pregnancy or breastfeeding.

Withdrawal Criteria:

  1. Gastroscopy duration exceeding 30 minutes.
  2. Adverse events that cannot be resolved with treatment.

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: Gerandomiseerd
  • Interventioneel model: Parallelle opdracht
  • Masker: Verdrievoudigen

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: Tegileridine Group

Tegileridine 0.01 mg/kg will be administered intravenously, followed 3 minutes later by intravenous propofol 1.5 mg/kg.

Tegileridine 0.01 mg/kg will be administered intravenously, followed 3 minutes later by intravenous propofol 1.5 mg/kg to induce sedation. The procedure will begin once the eyelash reflex is absent and the Modified Observer's Assessment of Alertness/Sedation (MOAA/S) score is ≤3. If signs of inadequate anesthesia occur during the examination, such as body movement, coughing, or a heart rate >100 beats/min, supplemental intravenous propofol 0.5-1.0 mg/kg will be administered at intervals of at least 2 minutes.

Tegileridine 0.01 mg/kg or sufentanil 0.1 μg/kg will be administered intravenously, followed 3 minutes later by intravenous propofol 1.5 mg/kg to induce sedation. The procedure will begin once the eyelash reflex is absent and the Modified Observer's Assessment of Alertness/Sedation (MOAA/S) score is ≤3. If signs of inadequate anesthesia occur during the examination, such as body movement, coughing, or a heart rate >100 beats/min, supplemental intravenous propofol 0.5-1.0 mg/kg will be administered at intervals of at least 2 minutes.

Actieve vergelijker: Sufentanil Group

Sufentanil 0.1 μg/kg will be administered intravenously, followed 3 minutes later by intravenous propofol 1.5 mg/kg.

Tegileridine 0.01 mg/kg or sufentanil 0.1 μg/kg will be administered intravenously, followed 3 minutes later by intravenous propofol 1.5 mg/kg to induce sedation. The procedure will begin once the eyelash reflex is absent and the Modified Observer's Assessment of Alertness/Sedation (MOAA/S) score is ≤3. If signs of inadequate anesthesia occur during the examination, such as body movement, coughing, or a heart rate >100 beats/min, supplemental intravenous propofol 0.5-1.0 mg/kg will be administered at intervals of at least 2 minutes.

Sufentanil 0.1 μg/kg will be administered intravenously, followed 3 minutes later by intravenous propofol 1.5 mg/kg to induce sedation. The procedure will begin once the eyelash reflex is absent and the Modified Observer's Assessment of Alertness/Sedation (MOAA/S) score is ≤3. If signs of inadequate anesthesia occur during the examination, such as body movement, coughing, or a heart rate >100 beats/min, supplemental intravenous propofol 0.5-1.0 mg/kg will be administered at intervals of at least 2 minutes.

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Incidence of Respiratory Depression
Tijdsspanne: Periprocedural, up to 2 hours

The primary outcome is the incidence of respiratory depression, defined as a respiratory rate <8 breaths/min or peripheral oxygen saturation (SpO₂) <90%.

Periprocedural, up to 2 hours

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Incidence of Hypotension
Tijdsspanne: Periprocedural, up to2 hours

Hypotension is defined as a decrease in systolic blood pressure (SBP) of more than 20% from baseline. The incidence of hypotension will be assessed during the periprocedural observation period and reported as the percentage of participants experiencing at least one episode of hypotension.

Periprocedural, up to2 hours
Incidence of Postoperative Nausea and Vomiting (PONV)
Tijdsspanne: Periprocedural, up to 24 hours after the endoscopic procedure

The incidence of postoperative nausea and vomiting (PONV) will be assessed within 24 hours after completion of the endoscopic procedure. PONV is defined as the occurrence of at least one episode of nausea, vomiting, or both during the observation period. The outcome will be reported as the percentage of participants experiencing PONV.

Periprocedural, up to 24 hours after the endoscopic procedure
Heart Rate
Tijdsspanne: Periprocedural, up to 2hours

Heart rate (beats/min) will be recorded at six prespecified time points: before entering the procedure room, after anesthesia induction, at endoscope insertion, 2 minutes after endoscope insertion, at endoscope withdrawal, and upon leaving the procedure room.

Periprocedural, up to 2hours
Mean Arterial Pressure
Tijdsspanne: Periprocedural, up to 2 hours

Mean arterial pressure (MAP, mmHg) will be recorded at the following six prespecified time points: before entering the procedure room, after anesthesia induction, at endoscope insertion, 2 minutes after endoscope insertion, at endoscope withdrawal, and upon leaving the procedure room.

Periprocedural, up to 2 hours
Respiratory Rate
Tijdsspanne: Periprocedural, up to 2 hours

Respiratory rate (breaths/min) will be recorded at six prespecified time points: before entering the procedure room, after anesthesia induction, at endoscope insertion, 2 minutes after endoscope insertion, at endoscope withdrawal, and upon leaving the procedure room.

Periprocedural, up to 2 hours
Peripheral Oxygen Saturation
Tijdsspanne: Periprocedural, up to 2 hours

Peripheral oxygen saturation (SpO₂, %) will be recorded at six prespecified time points: before entering the procedure room, after anesthesia induction, at endoscope insertion, 2 minutes after endoscope insertion, at endoscope withdrawal, and upon leaving the procedure room.

Periprocedural, up to 2 hours
Percentage of Participants With Successful Sedation Based on Body Movement at Endoscope Insertion and Rescue Sedative Use
Tijdsspanne: Periprocedural, at endoscope insertion for body movement and throughout the endoscopic procedure for rescue sedative use. Sedation success is determined at procedure completion.

Percentage of participants who meet both criteria for successful sedation: no body movement at endoscope insertion and no use of any rescue sedative other than the study drug during the endoscopic procedure.

Periprocedural, at endoscope insertion for body movement and throughout the endoscopic procedure for rescue sedative use. Sedation success is determined at procedure completion.
Number of Supplemental Propofol Doses and Total Propofol Dose
Tijdsspanne: Periprocedural, up to 2 hours

The number of supplemental propofol doses administered during the endoscopic procedure will be recorded for each participant. The total propofol dose (mg), including the initial dose and all supplemental doses, will also be calculated. Both outcomes will be assessed at the completion of the endoscopic procedure.

Periprocedural, up to 2 hours
Procedure Duration
Tijdsspanne: During the endoscopic procedure

Procedure duration is defined as the time interval from endoscope insertion to endoscope withdrawal, measured in minutes.

During the endoscopic procedure
Recovery Time
Tijdsspanne: Periprocedural,up to 2 hours

Recovery time is defined as the time interval from endoscope withdrawal to the time when the participant first meets the predefined discharge criteria for the post-anesthesia care unit (PACU), measured in minutes.

Periprocedural,up to 2 hours
Patient Satisfaction
Tijdsspanne: Post-procedure assessment.
Post-procedure assessment.
Sedation Success Rate
Tijdsspanne: At the end of the procedure.
At the end of the procedure.

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Sponsor

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

6 juni 2026

Primaire voltooiing (Geschat)

10 november 2026

Studie voltooiing (Geschat)

30 november 2026

Studieregistratiedata

Eerst ingediend

28 oktober 2026

Eerst ingediend dat voldeed aan de QC-criteria

13 november 2026

Eerst geplaatst (Werkelijk)

18 november 2026

Updates van studierecords

Laatste update geplaatst (Werkelijk)

18 november 2026

Laatste update ingediend die voldeed aan QC-criteria

13 november 2026

Laatst geverifieerd

1 november 2026

Meer informatie

Termen gerelateerd aan deze studie

Andere studie-ID-nummers

  • 2026-K68-01

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

NEE

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Nee

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .